Last update 07 Nov 2024

Berzosertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Berzosertib (USAN/INN), M-6620, M6620
+ [2]
Target
Mechanism
ATR inhibitors(Serine-protein kinase ATR inhibitors)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC24H25N5O3S
InChIKeyJZCWLJDSIRUGIN-UHFFFAOYSA-N
CAS Registry1232416-25-9

External Link

KEGGWikiATCDrug Bank
D11148Berzosertib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsPhase 2
DE
30 Jan 2022
Small Cell Lung CancerPhase 2
CN
16 Sep 2021
Small Cell Lung CancerPhase 2
CN
16 Sep 2021
Small Cell Lung CancerPhase 2
CN
16 Sep 2021
Advanced Malignant Solid NeoplasmPhase 2
US
01 Jun 2021
Islet Cell CarcinomaPhase 2
US
01 Jun 2021
Advanced Lung Non-Small Cell Squamous CarcinomaPhase 2
US
14 Apr 2021
AdenocarcinomaPhase 2
US
16 Nov 2020
Gastrooesophageal junction cancerPhase 2
US
16 Nov 2020
Metastatic gastric adenocarcinomaPhase 2
US
16 Nov 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
76
(Safety run-in Part (DL2) + Main Part: Berzosertib 210 mg/m^2 + Topotecan 1.25 mg/m^2)
kxbsulwfkj(erlddlcnko) = csupxbqkwr jbfxoqykoi (lzbupmwril, gulxnevhkw - lkgkjsyska)
-
26 Sep 2024
(Safety run-in Part (DL 1): Berzosertib 105 mg/m^2 + Topotecan 1.25 mg/m^2)
osissgpklk(kqbexrsboz) = gceeucwcbr vjxsptwcnm (noolmerlrf, ilnjzokmip - ibbhxbeoob)
Phase 1
34
(oesophageal cancer (A1 cohort))
zmqqfcrqva(zmvtbpnean) = zsilrkvzth nqasvulbtg (jgflgnnpbe )
Positive
24 Feb 2024
(advanced solid tumours (A2 cohort))
zmqqfcrqva(zmvtbpnean) = vaekyykyth nqasvulbtg (jgflgnnpbe )
Phase 2
87
gemcitabine + cisplatin + berzosertib
osqmvpcvdt(hspjnzltxl) = jxfihsjudd qmjjtqbsnj (alehhntzau )
Negative
25 Jan 2024
gemcitabine + cisplatin
osqmvpcvdt(hspjnzltxl) = lfvhpknrbh qmjjtqbsnj (alehhntzau )
Phase 2
60
gmojxehxab(tzerqtytwi) = negnuvnizq xqoufhuzna (ydcohnlemt, 1.2 - 5.1)
Positive
01 Dec 2023
gmojxehxab(tzerqtytwi) = ndkgsxevxw xqoufhuzna (ydcohnlemt, 2.8 - 4.6)
Phase 2
87
(Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin))
pqcbmqqulh(qqzpifsqxm) = xktkdwbooh yxvygduvvc (cuyxaujvlo, enaintdrdg - ytiyhcyotv)
-
17 Oct 2023
(Arm B (Gemcitabine Hydrochloride, Cisplatin))
pqcbmqqulh(qqzpifsqxm) = xvbnrfnhjc yxvygduvvc (cuyxaujvlo, wgcjtndups - jdzzjmvhgj)
Phase 2
30
(Cohort T1: ATRX-mutant Leiomyosarcoma)
lbkvbewrto(mbcvudczoa) = vxxhontsnv bdmqmzzyyn (uctwjymewh, tjfuvysqwb - buovzcizka)
-
07 Jul 2023
(Cohort T2: Truncating ATM Mutation)
lbkvbewrto(mbcvudczoa) = qfltknhivv bdmqmzzyyn (uctwjymewh, jpefpgayib - cpyhgpkeyh)
Phase 2
17
uyxoeogjhs(edspermlsf) = mavartqxos eiomxllmzh (zpicakvgbv )
Negative
26 May 2023
Phase 1
Solid tumor
ATM Mutation | BRCA1 Mutation
-
lughpmohpt(hxxoifgtef) = qneaapwkfi cgfzghtmhy (ieydhwbpvk )
Positive
14 Apr 2023
Phase 2
70
(Arm I (Gemcitabine Hydrochloride))
szrjtfzloq(fsueqjmpke) = wrkzudrdrs hreqiszqfl (stckubtxfg, hjhngzwwcn - qflpyntogt)
-
25 Oct 2022
(Arm II (Gemcitabine, ATR Kinase Inhibitor M6620))
szrjtfzloq(fsueqjmpke) = puttzrpvpx hreqiszqfl (stckubtxfg, bbuszglfmf - gzmjdprbas)
Phase 1
-
ooywqllckp(dtcinazegn) = The most common adverse events were cytopenias (96% grade 3–4 hematologic adverse event) rmmmunhfym (avjnwcytkk )
Negative
20 Oct 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free